Research programme: inflammation therapy - PLIVAAlternative Names: Inflammation therapy research programme - PLIVA
Latest Information Update: 16 Aug 2007
Price : $50 *
At a glance
- Originator PLIVA d.d.
- Mechanism of Action Cytokine inhibitors; Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Rheumatoid arthritis
Most Recent Events
- 20 Feb 2001 Preclinical development for Inflammation in Croatia (PO)
- 20 Feb 2001 Preclinical development for Rheumatoid arthritis in Croatia (PO)